Urbani Simona, Amadei Barbara, Tola Daniela, Pedrazzi Giuseppe, Sacchelli Luca, Cavallo Maria Cristina, Orlandini Alessandra, Missale Gabriele, Ferrari Carlo
Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology, Italy.
J Hepatol. 2008 Apr;48(4):548-58. doi: 10.1016/j.jhep.2007.12.014. Epub 2008 Jan 28.
BACKGROUND/AIMS: HCV-specific T cells in acute hepatitis C with subsequent chronic evolution are dysfunctional and most of them express PD-1. The aim of the study was to investigate to what extent the antiviral T cell function can be restored by reversing T cell exhaustion by PD-1/PD-L1 blockade and to assess whether this restoration is favored by IFN-alpha treatment.
PD-1 and PD-L1 expression was studied on T cells and dendritic cells, respectively, of 14 patients with acute hepatitis C and different evolutions of infection. The effect of anti-PD-L1 was analyzed on proliferation, cytokine production and cytolytic activity of CD4 and CD8 T cells.
While PD-1 expression dropped concurrently with spontaneous or IFN-alpha induced HCV-RNA decline, PD-L1 levels on dendritic cells increased during IFN-alpha treatment. Anti-PD-L1 antibodies improved expansion and cytokine production but not the cytolytic activity of HCV-specific T cells. This restoration tended to be greater at lower levels of viremia and PD-1 expression and during PEG-IFNalpha treatment.
PD-1/PD-L1 blockade has an immunoregulatory activity which may synergize with the antiviral effect of IFN-alpha therapy and should be thus explored further in long-lasting chronic HCV infections in the perspective of improving the efficacy of available antiviral treatments.
背景/目的:急性丙型肝炎中后续发展为慢性的丙型肝炎病毒(HCV)特异性T细胞功能失调,且大多数表达程序性死亡受体1(PD-1)。本研究旨在探讨通过PD-1/程序性死亡受体配体1(PD-L1)阻断逆转T细胞耗竭能在多大程度上恢复抗病毒T细胞功能,并评估这种恢复是否受α干扰素(IFN-α)治疗的促进。
分别研究了14例急性丙型肝炎且感染有不同转归患者的T细胞和树突状细胞上PD-1和PD-L1的表达。分析了抗PD-L1对CD4和CD8 T细胞增殖、细胞因子产生及细胞溶解活性的影响。
虽然PD-1表达随自发或IFN-α诱导的HCV-RNA下降而同时降低,但在IFN-α治疗期间树突状细胞上的PD-L1水平升高。抗PD-L1抗体改善了HCV特异性T细胞的扩增和细胞因子产生,但未改善其细胞溶解活性。在较低病毒血症水平和PD-1表达水平时以及聚乙二醇化干扰素α(PEG-IFNα)治疗期间,这种恢复往往更大。
PD-1/PD-L1阻断具有免疫调节活性,可能与IFN-α治疗的抗病毒作用协同,因此,从提高现有抗病毒治疗疗效的角度来看,应在长期慢性HCV感染中进一步探索。